Value through Innovation27 July 2016

Clinical Study Results

  • BI 811283 - Neoplasms
    Clinical Study Number 1247.1
    Study Indication Neoplasms
    Product BI 811283
    Generic Name BI 811283
    Lab Code
    Clinical Phase I
    Study Title

    An open phase I single dose escalation study of two dosing schedules of BI 811283 administered intravenously over 24 h continuous infusion in patients with advanced solid tumours with repeated administration in patients with clinical benefit

    Study Document Trial synopsis 1247.1 english
  • BI 811283 - Leukemia, Myeloid, Acute
    Clinical Study Number 1247.3
    Study Indication Leukemia, Myeloid, Acute
    Product BI 811283
    Generic Name BI 811283
    Lab Code
    Clinical Phase I
    Study Title

    An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatment

    Study Document Trial synopsis 1247.3 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.